Additionally, everolimus (or RAD001), a derivative rapalog developed for oral administration, has shown to induce cell cycle arrest through autophagy-mediated degradation of cyclin D1 in breast cancer cells [49], but promotes autophagy in aromatase inhibitor-resistant breast cancer cells as a mechanism of resistance [50]. The gene discussed is CCND1; the disease is breast carcinoma.